

LETTERS

Standing firm

Readers offer views on a number of topics: "[R]esidents of Alaska will find . . . benefits" from a "world-class" ionosphere research facility (below); publishing raw genetic sequences will "not likely" thwart the patenting and commercialization of gene products; to avoid "victimization" of unknowing authors, journals should insist that co-authors consult one another before their names appear on a paper; the challenge of predicting the "behavior of ecological systems" should be "tackled vigorously"; "flexible funds" should be made available to medical schools for the "support [of] their academic objectives"; and international support for the "biodiversity information associated with natural history museum collections" should be made more widely available.



HAARP Facility in Alaska

With respect to the News & Comment article "Ionosphere research lab sparks fears in Alaska" by Lisa Busch (21 Feb., p. 1060), I would like to make two points.

First, the anti-HAARP (High-Frequency Active Auroral Research Program) activists overestimated the power of the Gakona, Alaska, facility by a factor of more than a million and then used statements in patents (1) to fuel speculations on the part of the public about possible effects such as weather manipulations, mind warping, and communication disruptions. This incorrect information has been refuted in hearings in the Alaska legislature, in a video prepared by Senator Frank H. Murkowski (R-AK) for airing in Alaska, and at open-house sessions at the site for interested visitors.

Second, the Gakona site is now intended to be a world-class facility for studying the upper atmosphere, although the func-

tion has evolved from an over-the-horizon radar (never constructed), to a high-frequency facility (under construction) to generate ELF (Extremely Low Frequency) radio waves in the ionosphere, to a major center for upper atmosphere studies using a variety of diagnostics (some in place) with a powerful incoherent scatter radar (ISR) as the core instrument (to be constructed). The core instrument will join with existing ISRs at Svalbard and Tromsø in Norway; Sondrestrom, Greenland; and Boston, Massachusetts, and with the proposed ISR at Resolute Bay, Canada, to form an Arctic network of radars to observe virtually the whole Polar Cap and to track disturbances produced by solar inputs in the form of waves and particles. The network will be a remarkable addition to the tools available to the atmospheric science community with applications to space weather, Arctic and satellite communications, and electric power-grid problems.

In the early days of the Arecibo Observatory in Puerto Rico there were concerns expressed about the facility, but these have long since been replaced by satisfaction with the scientific outcomes and the benefits to the local economy. The residents of Alaska will find similar benefits.

William E. Gordon

*Distinguished Professor Emeritus,
Department of Electrical Engineering,
Rice University,
Houston, TX 77005-1892, USA
E-mail: bgordon@spacsun.rice.edu*

References

1. B. J. Eastlund, Patent No. 4686605, 11 August 1987; and S. Ramo, Patent No. 4712155, 8 December 1987; B. J. Eastlund, Patent No. 5038664, 13 August 1991.


Sequence Patents

In Eliot Marshall's News & Comment article of 7 February (p. 777), it is suggested that the National Institutes of Health's (NIH's) insistence on rapid release of gene sequence information arising from their large-scale sequencing programs and avoidance of patent filing on such information is in violation of the Bayh-Dole Act. This is not correct.

Sequence fragments of unknown utility, although important starting points for further research, are likely not to be inven-

PROTEIN
CONCENTRATION

Maximum Throughput Minimum Time



Ultrafree-®

Centrifugal Filter Devices let you concentrate or purify protein solutions in one quick and easy step. Even microliter amounts of material can be processed with minimal sample loss.

Choose from three devices:

Ultrafree-0.5 for concentrating up to 0.5 mL down to 20 µL in 10 min.*

Ultrafree-4 for concentrating up to 4 mL down to 50 µL in 15 min.*

Ultrafree-15 for concentrating up to 15 mL down to 300 µL in 30 min.*

Each device incorporates the Biomax™ (PES) membrane and a novel vertical design for fast concentration – without spinning to dryness. Sample recovery from the concentrate pocket or filtrate tube is convenient after a single spin.

Call or fax for more information.

U.S. and Canada,
call Technical Services:

1-800-MILLIPORE (645-5476).

To place an order, call Fisher

Scientific: 1-800-766-7000

(in Canada, call 1-800-234-7437).

In Japan, call: (03) 5442-9716;

in Asia, call: (852) 2803-9111;

in Europe, fax: +33-3.88.38.91.95

*1 mg/mL Bovine Serum Albumin, Biomax-10

MILLIPORE

www.millipore.com/ultrafree

e-mail: tech_service@millipore.com

Circle No. 2 on Readers' Service Card